Corporate$PVLA2:41 PM ET

Palvella Gains After FDA Grants Priority Review for Qtorin

By BORSA NewsroomPublished Oct 28, 2026, 2:41 PM EDTUpdated Oct 28, 2026, 2:42 PM EDT

FDA granted priority review for Qtorin (rapamycin) for microcystic lymphatic malformations. Stock up 8.7% to $144.49. PDUFA date Feb. 28, 2027.

Sentimentbullish 80

Strongly bullish · 80 of 100

Impact50

low · stays off the top drivers

Confidence80%

high confidence · single wire

Eventdeveloping

v1 · alerted to followers

WHAT WE KNOW

FDA granted priority review for Qtorin.
Qtorin could become first FDA-approved therapy for microcystic lymphatic malformations.